Five Prime Therapeutics Stock Analysis (NASDAQ:FPRX)

Add to My Stocks
$30.22 $0.79 (2.55%) FPRX stock closing price Jul 25, 2017 (Closing)
Watch Robo Advisor Video of FPRX Stock Analysis
Five Prime Therapeutics
Updated on : Jul 25, 2017
previous close
FPRX 30.2 (0%)
S&P 500 2477.1 (0%)
Closing Price On: Jul 25, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Sector :
5 Quarter Revenue
Revenue Growth
Compared to the industry
Operating Profit
Operating Margin:
Sector Average:
5 Quarter Net Profit
Net Margins
LTM Margin
Cash Flow
Operating cash flow:
Net Income:
Recent Growth
Operating Margins
Net Margins
FCF Margin
PE Valuation
PS Valuation
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
Industry PS :
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Equity:
Free Cash Flow Margin:
Double Tap To Exit Full Screen

Five Prime Therapeutics Analysis Video

136 5 2

View Five Prime Therapeutics stock analysis video. This is our FPRX analyst opinion covering the buy and sell arguments for FPRX stock.

Five Prime Therapeutics Inc Stock Rating (1.8/5)

Our Five Prime Therapeutics stock opinion is based on fundamentals of the company. This Five Prime Therapeutics stock analysis is based on latest Q1 earnings for 2017. The stock price analysis takes into account a company's valuation metrics.

Should you buy FPRX stock?

  • The Year Over Year (YoY) revenue growth for Five Prime Therapeutics was 55.5% in 2017 Q1.

Should you sell FPRX stock?

  • Five Prime Therapeutics registered a negative operating margin of -329.2% (average) over the Trailing Twelve Months (TTM).
  • Over the last 12 months, Five Prime Therapeutics had an average Net loss of -250.9%.
  • The company does not have profits. Hence the PE ratio is meaningless for FPRX stock.
  • The company is trading at a price to sales multiple of 24.4, which is overvalued in comparison to the Medical-Biomed-Genetics industry average multiple of 5.3.
  • Five Prime Therapeutics has a negative ROE (Return On Equity) of -21.4%, indicating the company is not profitable.
  • The company has negative Free Cash Flows (FCF), with a negative FCF margin of -293.3%.

Comments on this video and Five Prime Therapeutics stock